Antibody Response to Covid-19 mRNA Vaccine (Comirnaty), in Myeloma Patients Treated with High-dose Melphalan and/or Immunotherapy
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Covid-19 infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) was first reported in December 2019 in Wuhan, China, and has since become a global pandemic. Symptoms range from none (subclinical infections) to acute respiratory failure including acute respiratory distress syndrome (ARDS). Risk factors for a severe course of disease include high age, male gender and comorbidities such as cardiovascular disease, diabetes, chronic obstructive pulmonary disease (COPD) and cancer. Several studies have reported that the overall risk of cancer patients to become infected and developing critical symptoms requiring intensive care unit (ICU) admission and death is high. Notably, patients with hematological cancers seem to be at even higher risk of fatal outcome than those with solid tumors.1 A high but variable mortality (27-57%) in Covid-19 hospitalized patients with a plasma cell disorder was reported by the International Myeloma Society.